1YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| PKI 14-22 amide,myristoylated | PKI 14-22 AMIDE, MYRISTOYLATED | 201422-03-9 |
| GIP (3-42), human | GIP (3 - 42), human | 1802086-25-4 |
| PF-03814735 | N-[2-[(1S,4R)-6-[[4-(环丁基氨基)-5-(三氟甲基)-2-嘧啶基]氨基]-1,2,3,4-四氢萘-1,4-亚氨-9-基]-2-氧代乙基]乙酰胺 | 942487-16-3 |
| PRT062607 Hydrochloride | PRT062607 (HYDROCHLORIDE) | 1370261-97-4 |
| LDN-192960 | 3-[(2,7-二甲氧基吖啶-9-基)硫基]丙胺 | 184582-62-5 |
| Tirabrutinib | 替拉鲁替尼 | 1351636-18-4 |
| Formononetin | 刺芒柄花素 | 485-72-3 |
| Insulin(cattle) | 牛胰岛素 | 11070-73-8 |
| LDN-192960 hydrochloride | LDN-192960 HYDROCHLORIDE | 2309172-48-1 |
| c-Fms-IN-2 | 791587-67-2 | 791587-67-2 |
| IWP-O1 | IWP-O1 | 2074607-48-8 |
| Trapidil | 乐可安 | 15421-84-8 |
| Y-27632 | Y-27632二盐酸盐 | 146986-50-7 |
| AZM475271 | 476159-98-5 | 476159-98-5 |
| CGP77675 | CGP 77675; CGP-77675 | 234772-64-6 |
| JI-101 | JI-101 | 900573-88-8 |
| Flumatinib mesylate | 甲磺酸氟马替尼/氟马替尼 | 895519-91-2 |
| Crizotinib hydrochloride | 克里唑替尼盐酸 | 1415560-69-8 |
| CCT241736 | CS-2683 | 1402709-93-6 |
| Pexidartinib hydrochloride | 培西达替尼盐酸盐 | 2040295-03-0 |
| DCC-3014 | DCC3014 | 1628606-05-2 |
| H-89 | N-[2-[P-溴苯丙烯盐基氨基]乙基]-5-异喹啉磺酰胺 | 127243-85-0 |
| SANT-1 | SANT1 | 304909-07-7 |
| Bilobetin | 7-去甲基银杏双黄酮 | 521-32-4 |
| Tyrphostin A9 | 酪氨酸磷酸化抑制剂A9 | 10537-47-0 |
| BIBF 1202 | BIBF 1202 | 894783-71-2 |
| SYN1143 | N-[3-氟-4-[(7-甲氧基喹啉-4-基)氧基]苯基]-1-(2-羟基-2-甲基丙基)-5-甲基-3-氧代-2-苯基-2,3-二氢-1H-吡唑-4-甲酰胺 | 913376-84-8 |
| Nocodazole | 诺考达唑 | 31430-18-9 |
| Y-33075 dihydrochloride | Y39983 HYDROCHLORIDE | 173897-44-4 |
| ALK inhibitor 1 | 2-[[5-溴-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 | 761436-81-1 |
| VC-4718 | PND1186 | 1061353-68-1 |
| AMG 925 | AMG-925 | 1401033-86-0 |
| PP58 | Pyrido[2,3-d]pyrimidin-7(8H)-one,2-[[4-(2-aminoethoxy)phenyl]amino]-6-(2,6-dichlorophenyl)-8-methyl- | 212391-58-7 |
| SCR-1481B1 | 麦他替尼胺丁三醇 | 1174161-86-4 |
| GNF-6231 | GNF6231 | 1243245-18-2 |
| SKL2001 | SKL2001 | 909089-13-0 |
| ASP5878 | ASP-5878 | 1453208-66-6 |
| DDR Inhibitor | 1644069-80-6 | 1644069-80-6 |
| Bevacizumab | 贝伐珠单抗 | 216974-75-3 |
| CREBtide | 多肽CREBtide | 149155-45-3 |
| A 419259 trihydrochloride | 7-[反式-4-(4-甲基-1-哌嗪基)环己基]-5-(4-苯氧基苯基)-7H-吡咯并[2,3-D]嘧啶-4-胺三盐酸盐 | 1435934-25-0 |
| AC710 | N-[4-[[[[5-(叔丁基)-3-异恶唑基]氨基]羰基]氨基]苯基]-5-[(1-乙基-2,2,6,6-四甲基-4-哌啶基)氧基]-2-吡啶甲酰胺 | 1351522-04-7 |
| QL47 | 1469988-75-7 | 1469988-75-7 |
| BO-264 | BO-264 | 2408648-20-2 |
| Metadoxine | 美他多辛 | 74536-44-0 |
| Linifanib | 利尼伐尼 | 796967-16-3 |
| EOC317 | ACTB-1003 | 939805-30-8 |
| TAK-593 | 1005780-62-0 | 1005780-62-0 |
| GDC-0834 Racemate | N-[3-[6-[[4-(1,4-二甲基-3-氧代-2-哌嗪基)苯基]氨基]-4,5-二氢-4-甲基-5-氧代-2-吡嗪基]-2-甲基苯基]-4,5,6,7-四氢苯并[B]噻吩-2-甲酰胺 | 1133432-46-8 |
| DDR1-IN-2 | DDR1-IN-2 | 1429617-90-2 |
| c-Fms-IN-1 | C-FMS-IN-1 | 885703-64-0 |
| Tanshinone IIA | 丹参酮 IIA | 568-72-9 |
| Fangchinoline | 防己诺林碱 | 436-77-1 |
| Y-33075 | (R)-4-(1-氨基乙基)-N-1H-吡咯并[2,3-B]吡啶-4-基苯甲酰胺 | 199433-58-4 |
| ALK inhibitor 2 | 2-[[5-氯-2-[[2-甲氧基-4-(4-甲基-1-哌嗪基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯磺酰胺 | 761438-38-4 |
| Lucitanib | 德立替尼 | 1058137-23-7 |
| BMX-IN-1 | N-[2-甲基-5-[9-[4-[(甲基磺酰基)氨基]苯基]-2-氧代苯并[H]-1,6-萘啶-1(2H)-基]苯基]-2-丙烯酰胺 | 1431525-23-3 |
| CEP-37440 | CEP-37440 | 1391712-60-9 |
| NAMI-A | 201653-76-1 | 201653-76-1 |
| XMU-MP-1 | XMU-MP-1 | 2061980-01-4 |
| MK-4101 | 5-(3,3-二氟环丁基)-3-[4-[4-甲基-5-[2-(三氟甲基)苯基]-4H-1,2,4-三唑-3-基]双环[2.2.2]辛烷-1-基]-1,2,4-恶二唑 | 935273-79-3 |
| CCG215022 | CCG215022 | 1813527-81-9 |
| Scutellarein | 野黄芩素 | 529-53-3 |
| Pz-1 | 1800505-64-9 | 1800505-64-9 |
| Kemptide | 肯普肽 | 65189-71-1 |
| NVP-ACC789 | N-(3-溴-4-甲基苯基)-4-(4-吡啶甲基)-1-酞嗪胺 | 300842-64-2 |
| Ciliobrevin A | HPI-4 | 302803-72-1 |
| Ibrutinib deacryloylpiperidine | 伊布替尼中间体N-2 | 330786-24-8 |
| Ceritinib dihydrochloride | 双盐酸盐色瑞替尼 | 1380575-43-8 |
| Merestinib dihydrochloride | N-[3-氟-4-[[1-甲基-6-(1H-吡唑-4-基)-1H-吲唑-5-基]氧基]苯基]-1-(4-氟苯基)-1,2-二氢-6-甲基-2-氧代-3-吡啶甲酰胺二盐酸盐 | 1206801-37-7 |
| PLX647 | 10MG | 873786-09-5 |
| Ramucirumab | 雷莫芦单抗 | 947687-13-0 |
| SRI-011381 hydrochloride | SRI-011381 (hydrochloride) | 2070014-88-7 |
| Insulin (human) | 重组人胰岛素 | 11061-68-0 |
| Imatinib | 伊马替尼 | 152459-95-5 |
| Rho-Kinase-IN-1 | Rho-Kinase-IN-1 | 1035094-83-7 |
| Ilorasertib hydrochloride | ILORASERTIB HYDROCHLORIDE (ABT-348 HYDROCHLORIDE) | 1847485-91-9 |
| Toxoflavin | 毒黄素 | 84-82-2 |
| Imatinib D8 | 伊马替尼D8 | 1092942-82-9 |
| BAY 61-3606 dihydrochloride | BAY 61-3606 | 648903-57-5 |
| c-Met inhibitor 1 | 3-[(2-甲基-2H-吲唑-5-基)硫基]-6-(1-甲基-1H-吡唑-4-基)-1,2,4-三唑并[4,3-B]哒嗪 | 1357072-61-7 |
| GZD824 | GZD824 | 1257628-77-5 |
| GDC-0834 | CS-1263 | 1133432-49-1 |
| GDC-0834 S-enantiomer | 化合物 T11378 | 1133432-50-4 |
| GZD824 dimesylate | GZD824DIMESYLATE | 1421783-64-3 |
| 1-Naphthyl PP1 hydrochloride | 1-叔丁基-3-(1-萘基)-1H-吡唑并[3,4-D]嘧啶-4-胺盐酸盐 | 956025-47-1 |
| Indirubin Derivative E804 | Indirubin Derivative E804 | 854171-35-0 |
| KYA1797K | CS-2581 | 1956356-56-1 |
| CA-4948 | 4-Oxazolecarboxamide, N-[5-[(3R)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)- | 1801344-14-8 |
| RET V804M-IN-1 | 化合物RET V804M-IN-1 | 2414909-94-5 |
| I-OMe-Tyrphostin AG 538 | I-OME-AG 538 | 1094048-77-7 |
| AG-13958 | N-[2-氟-5-[[3-[(1E)-2-(2-吡啶基)乙烯基]-1H-吲唑-6-基]氨基]苯基]-1,3-二甲基-1H-吡唑-5-甲酰胺 | 319460-94-1 |
| DDR1-IN-1 | N-[3-[(2,3-二氢-2-氧代-1H-吲哚-5-基)氧基]-4-甲基苯基]-4-[(4-乙基-1-哌嗪基)甲基]-3-(三氟甲基)苯甲酰胺 | 1449685-96-4 |
| VEGFR-2-IN-5 | N2-[4-[(3-氨基丙基)氨基]苯基]-N4-(5-环丙基-1H-吡唑-3-基)-2,4-嘧啶二胺 | 1430089-64-7 |
| BBT594 | BBT594 | 882405-89-2 |
| Glesatinib hydrochloride | CS-2642 | 1123838-51-6 |
| PKI(5-24) | THR-THR-TYR-ALA-ASP-PHE-ILE-ALA-SER-GLY-ARG-THR-GLY-ARG-ARG-ASN-ALA-ILE-HIS-ASP | 99534-03-9 |
| CH6953755 | CH6953755 | 2055918-71-1 |
| Imatinib D4 | [2H4]-伊马替尼 | 1134803-16-9 |
| 7-Hydroxy-4-chromone | 7-羟基色原酮 | 59887-89-7 |
联系方式
